Merck & Co., Inc. is closing down the Keytruda (pembrolizumab) and vibostolimab coformulation arm of a Phase III melanoma trial after an analysis showed a higher dropout rate compared with the Keytruda-only arm due to adverse events, chalking up another loss for anti-PD-1/TIGIT combinations.
The Rahway, NJ-based drug maker said 13 May that a preplanned analysis of the KeyVibe-010 trial comparing the coformulation against...